Affinity Asset Advisors »

Ascendis Pharma AS shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Ascendis Pharma AS (ASND) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Ascendis Pharma AS

Tip: Access up to 7 years of quarterly data

All positions including Ascendis Pharma AS held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ascendis Pharma AS by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $8.0M 30k 266.72

More positions owned by Affinity Asset Advisors

Roivant Sciences SHS (ROIV)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Xenon Pharmaceuticals (XENE)
Erasca (ERAS)
Alkermes SHS (ALKS)
Insmed Com Par $.01 (INSM)
Moderna Put Option (MRNA)
Praxis Precision Medicines I Com New (PRAX)
Oruka Therapeutics (ORKA)
Anaptysbio Inc Common (ANAB)
Avalo Therapeutics Com New (AVTX)
Cytokinetics Com New (CYTK)
Revolution Medicines (RVMD)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Affinity Asset Advisors

Top funds holding Ascendis Pharma AS

RA Capital Management
venBio Select Advisor
Westfield Capital Management Company
Jupiter Topco
FMR
Artisan Partners Limited Partnership
BlackRock
Capital Research and Management Company - Division 3
Massachusetts Financial Services
Franklin Resources
Wellington Management Company
T. Rowe Price Associates
American Century Companies
Perceptive Advisors
Principal Financial Group

View all funds holding Ascendis Pharma AS